On February 7, 2015, the National Lipid Association (NLA) Strategic Planning Committee (Committee) convened in Orlando, Florida. The Committee reaffirmed the mission and goals of the organization, and assigned the following as the priorities and deadlines:
Part Two Provides New Recommendations for Managing Cholesterol in Diverse and Underrepresented Ethnic and Racial Groups along with Recommendations that Cross the Life Span from Children to Seniors
CHICAGO — Today, the National Lipid Association (NLA) released a draft of its Part Two Recommendations based on a panel of independent experts.
Two new PCSK9 monoclonal antibodies have been given a nod of approval to the Food and Drug Administration (FDA). The FDA Endocrinologic and Metabolic Drugs Advisory Committee reviewed the evidence on the new class of cholesterol-lowering drugs and recommended that the FDA should approve the new class of LDL-lowering drugs.
This is great news, especially for high risk patients and for Familial Hypercholesterolemia (FH) patients who are not at their LDL-C and non-HDL-C goals on optimal therapy. The NLA is excited about this decision by the FDA advisory committee.
.jpg)
.png)
